Industry

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs BEIJING & ALAMEDA, Calif. & TAIPEI, Taiwan–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable … [Read more…]

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies GHENT, Belgium–(BUSINESS WIRE)–#Parkinson–MRM Health NV, a … [Read more…]

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates Agreement provides Johnson & Johnson pharmaceutical products an exemption from U.S. tariffs Company announces two new additional manufacturing facilities to be built in North Carolina and Pennsylvania; continues to deliver on $55 billion U.S. investment NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson … [Read more…]

FineHeart Secures €83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)

€35 million Series C funding to accelerate the clinical and industrial development of FlowMaker® €48 million in grants from the IPCEI Tech4Cure program to structure the European Active Implantable Medical Devices (AIMD) sector BORDEAUX, France–(BUSINESS WIRE)–FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of … [Read more…]

New Year, New You: Walmart Launches Better Care Services and Rolls Back Prices on 1,000+ Wellness Essentials

BENTONVILLE, Ark.–(BUSINESS WIRE)–Walmart is starting the new year by making healthcare easier and more affordable with the launch of Better Care Services. This one-stop digital destination is designed to help empower millions of customers to take control of their health journeys with ease, transparency and confidence. “We know that when heath care feels hard, many … [Read more…]

During J. P. Morgan Healthcare Week, Biotech Showcase™ Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma Partners and Media

Join Bristol Myers Squibb, Genentech, Google, J.P. Morgan, Novo Nordisk, Pappas Capital, Amazon Web Services, BIO, Members of the Media, and 1,200+ Investors Registration and Partnering Platform Access Now Open SAN FRANCISCO–(BUSINESS WIRE)–#biotechshowcase–More than 3,000 leaders within biotechnology are registered to attend Biotech Showcase 2026 during J.P. Morgan Healthcare Week for unmatched opportunity to forge … [Read more…]

VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS

~ Designation enables an enhanced development path for VTx-002 and underscores its disease-modifying potential in ALS, a universally fatal disease with no cure ~ ~ Milestone follows recent IND clearance and supports continued advancement of VTx-002 toward the planned PIONEER-ALS Phase 1/2 clinical study ~ AMSTERDAM & BOSTON–(BUSINESS WIRE)–VectorY Therapeutics, a leader in vectorized antibody … [Read more…]

FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026 in San Francisco, CA. With more than a decade of expertise, FJBio has supported over … [Read more…]

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference

LEIDEN, Netherlands–(BUSINESS WIRE)–#Adults—Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation … [Read more…]

Novotech Appoints Anand Tharmaratnam as New CEO

SINGAPORE–(BUSINESS WIRE)–#ClinicalTrials–Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the appointment of Dr. Anand Tharmaratnam as its new Chief Executive Officer. Dr. Tharmaratnam brings nearly three decades of experience in the global CRO industry and has served as Novotech Chairman since 2021. He commenced as Chairman and CEO on … [Read more…]